Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 2/20 | 0.35 |
| ▸ | LPL | P06858 | 2/20 | 0.35 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.35 |
| ▸ | PTGES | O14684 | 2/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.33 |
| ▸ | DRD2 | P14416 | 1/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | HTR6 | P50406 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | GHSR | Q92847 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL236621 | 0.96 | MAOA (0.38) | KIF11LPLLIPGPTGESMAOA | |
| SCHEMBL232960 | 0.94 | LPL (0.37) | KIF11LPLLIPGPTGESTAAR1 | |
| SCHEMBL236218 | 0.92 | TAAR1 (0.41) | KIF11TAAR1DRD2DRD1CYP2D6 | |
| SCHEMBL15461600 | 0.91 | LPL (0.40) | LPLLIPGPTGESDRD2DRD1 | |
| SCHEMBL235253 | 0.89 | TAAR1 (0.35) | KIF11LPLLIPGPTGESTAAR1 | |
| SCHEMBL233408 | 0.88 | MAPT (0.36) | KIF11LPLLIPGPTGESTAAR1 | |
| SCHEMBL232700 | 0.86 | ENPP2 (0.39) | PTGESCYP2D6HRH4HRH3 | |
| SCHEMBL235866 | 0.85 | MEN1 (0.41) | PTGESTAAR1CYP2D6HRH4HRH3 | |
| SCHEMBL236313 | 0.83 | CYP2D6 (0.39) | PTGESTAAR1DRD2DRD1CYP2D6 | |
| SCHEMBL236307 | 0.83 | PTGES (0.37) | PTGESTAAR1DRD2DRD1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150329473-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. | 2015-11-19 | — | — | US | claimed |
| US-8389771-B2 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA, INC. (US) | 2013-03-05 | — | — | US | claimed |
| US-20130030026-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2013-01-31 | — | — | US | claimed |
| US-20130018077-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA INC. (US) | 2013-01-17 | — | — | US | claimed |
| US-8299307-B2 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2012-10-30 | — | — | US | claimed |
| EP-2076122-A2 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | Acucela, Inc. (US) | 2009-07-08 | — | — | EP | claimed |
| US-20090062353-A1 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA, INC. | 2009-03-05 | — | — | US | claimed |
| WO-2009005794-A2 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2009-01-08 | — | — | WO | claimed |
| US-11795136-B2 | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases | ACUCELA INC. (US) | 2023-10-24 | — | — | US | disclosed |
| US-20210171435-A1 | Methods for the Treatment of Diabetic Retinopathy and other Ophthalmic Diseases | ACUCELA INC. | 2021-06-10 | — | — | US | disclosed |
| US-10730825-B2 | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases | ACUCELA INC. (US) | 2020-08-04 | — | — | US | disclosed |
| EP-2844636-B1 | METHODS FOR THE TREATMENT OF PROLIFERATIVE DIABETIC RETINOPATHY | ACUCELA INC (US) | 2020-04-22 | — | — | EP | disclosed |
| US-9957224-B2 | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases | ACUCELA INC (US) | 2018-05-01 | — | — | US | disclosed |
| US-9464033-B2 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA INC. (US) | 2016-10-11 | — | — | US | disclosed |
| WO-2009058216-A1 | AMINE DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| US-20090062353-A1 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA, INC. | 2009-03-05 | — | — | US | disclosed |
| US-20090062353-A1 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA, INC. | 2009-03-05 | — | — | US | disclosed |
| US-20090062353-A1 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | ACUCELA, INC. | 2009-03-05 | — | — | US | disclosed |
| WO-2009005794-A2 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
| WO-2009005794-A2 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | ACUCELA, INC. (US) | 2009-01-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018077-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, STARD3, PDE6C | KIF11 2636/4885LPL 161/4885LIPG 218/4885 |
| US-10730825-B2 | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases | ALDH1A2, ALDH1A3, RBP4 | KIF11 3259/4885LPL 524/4885LIPG 144/4885 |
| US-20090062353-A1 | Alkynyl phenyl derivative compounds for treating ophthalmic diseases and disorders | PDE6D, STARD3, PDE6C | KIF11 2636/4885LPL 161/4885LIPG 218/4885 |
| US-20130030026-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, STARD3, PDE6C | KIF11 2636/4885LPL 161/4885LIPG 218/4885 |
| US-11795136-B2 | Methods for the treatment of diabetic retinopathy and other ophthalmic diseases | ALDH1A2, ALDH1A3, RBP4 | KIF11 3259/4885LPL 524/4885LIPG 144/4885 |
| US-20210171435-A1 | Methods for the Treatment of Diabetic Retinopathy and other Ophthalmic Diseases | ALDH1A2, ALDH1A3, RBP4 | KIF11 3259/4885LPL 524/4885LIPG 144/4885 |
| US-20150329473-A1 | ALKYNYL PHENYL DERIVATIVE COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS | PDE6D, STARD3, PDE6C | KIF11 2636/4885LPL 161/4885LIPG 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.